Innovating Works

INTIGT

Financiado
Identification of novel targets to improve glioblastoma therapy
Glioblastoma (GBM) is the most common malignant primary brain tumour in adults. The current standard of care is surgical resection of GBM tumours followed by chemotherapy and ionizing radiation (IR). Despite these intense efforts,... Glioblastoma (GBM) is the most common malignant primary brain tumour in adults. The current standard of care is surgical resection of GBM tumours followed by chemotherapy and ionizing radiation (IR). Despite these intense efforts, GBM tumours remain incurable and the median survival rate of GBM patients remains only ~15 months. This dismal clinical outcome underscores the urgent need for novel therapeutic strategies for GBM. At the cellular level, GBM tumours contain a rare population of self-renewing, highly invasive stem cells termed brain tumour stem cells (BTSCs) that are endowed with properties to proliferate, spur the growth of new tumours, and at the same time, evade IR and chemotherapy. Thus eradicating BTSCs in tumour bulk represents a promising approach to fight brain cancer at its root. However, there are presently no treatments targeting BTSCs in GBM. Recent preliminary data obtained by the applicant at McGill University (Montreal, Canada) led to the hypothesis that a novel signalling pathway, galectin1/HOXA5, controls BTSC behaviour and represents a promising target to eradicate BTSCs. Thus, the applicant will join the Laboratoire de l’Angiogenèse et du Microenvironnement des Cancers at University of Bordeaux to test this hypothesis, under the supervision of Pr. Bikfalvi. The host, the supervisor and the candidate represents the perfect match to realise this proposal and the project is designed to bring forth a two-transfer of knowledge between the host and the candidate. The advanced techniques and transferable skills that the candidate acquires through this research will largely broaden his competencies and increase his employability as an independent researcher in the field of neuro-oncology. Results generated through this proposal will be innovative and of clinical relevance for GBM patients. This study has the potential to open new therapeutic avenues and pave the way for future clinical trials for better treatment of these deadly tumours. ver más
31/08/2025
UBx
212K€
Duración del proyecto: 33 meses Fecha Inicio: 2022-11-24
Fecha Fin: 2025-08-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-24
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 212K€
Líder del proyecto
UNIVERSITE DE BORDEAUX No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5